Azerbaijan vs El Salvador: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Azerbaijan
- El Salvador
How they compare
Azerbaijan currently reports 607.42 deaths against 521.19 deaths in El Salvador, a difference of 86.23 deaths.
That makes Azerbaijan's figure about 1.2 times El Salvador's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was El Salvador ahead.
Azerbaijan ranks 87th and El Salvador ranks 90th of 157 countries.
Across the 4 decades both report, Azerbaijan averaged higher in 1 and El Salvador in 2.
Head to head by decade
| Decade | Azerbaijan | El Salvador | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 12.14 deaths | 374.61 deaths | 362.47 deaths | El Salvador |
| 2010s | 273.78 deaths | 792.19 deaths | 518.41 deaths | El Salvador |
| 2020s | 561.31 deaths | 558.8 deaths | 2.51 deaths | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Azerbaijan or El Salvador?
- Azerbaijan, at 607.42 deaths against 521.19 deaths in El Salvador as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Azerbaijan and El Salvador?
- 86.23 deaths, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and El Salvador?
- 35 years are reported by both, from 1990 to 2024.
- How do Azerbaijan and El Salvador rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Azerbaijan ranks 87th and El Salvador ranks 90th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.